STOK Stock Overview
An early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Stoke Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.68 |
| 52 Week High | US$17.58 |
| 52 Week Low | US$4.09 |
| Beta | 0.94 |
| 1 Month Change | 2.19% |
| 3 Month Change | -11.98% |
| 1 Year Change | 119.14% |
| 3 Year Change | -45.85% |
| 5 Year Change | -56.06% |
| Change since IPO | -54.32% |
Recent News & Updates
Recent updates
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Nov 08
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Nov 06Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Shareholder Returns
| STOK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.2% | -3.6% | -2.4% |
| 1Y | 119.1% | -2.6% | 23.4% |
Return vs Industry: STOK exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: STOK exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| STOK volatility | |
|---|---|
| STOK Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STOK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STOK's weekly volatility has decreased from 15% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 110 | Ed Kaye | www.stoketherapeutics.com |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
Stoke Therapeutics, Inc. Fundamentals Summary
| STOK fundamental statistics | |
|---|---|
| Market cap | US$618.65m |
| Earnings (TTM) | -US$105.46m |
| Revenue (TTM) | US$16.74m |
37.0x
P/S Ratio-5.9x
P/E RatioIs STOK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STOK income statement (TTM) | |
|---|---|
| Revenue | US$16.74m |
| Cost of Revenue | US$0 |
| Gross Profit | US$16.74m |
| Other Expenses | US$122.20m |
| Earnings | -US$105.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 100.00% |
| Net Profit Margin | -629.86% |
| Debt/Equity Ratio | 0% |
How did STOK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Stoke Therapeutics, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |